<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832531</url>
  </required_header>
  <id_info>
    <org_study_id>INVICTUS - ASA</org_study_id>
    <nct_id>NCT02832531</nct_id>
  </id_info>
  <brief_title>INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority</brief_title>
  <acronym>INVICTUS-ASA</acronym>
  <official_title>INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This program is a comprehensive evaluation of rheumatic valvular heart disease (RVHD), Atrial&#xD;
      fibrillation (AF)/flutter and stroke.&#xD;
&#xD;
      A prospective, randomized, open-label superiority trial comparing rivaroxaban to aspirin in&#xD;
      high risk patients either with AF and unsuitable for VKA or without AF and with high risk&#xD;
      factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to the first occurrence of Stroke or systemic embolism</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Stroke (Ischemic, hemorrhagic or undetermined type)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to the first occurrence of Myocardial Infarction (MI)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to time of vascular death</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Vascular death includes death due to stroke, myocardial infarction, heart failure or cardiogenic shock, sudden death or any other death due to cardiovascular causes. In addition, death due to hemorrhage will be included</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time from randomization to the first occurrence of a Major bleed</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Using the International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Rheumatic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban (15 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 15 mg od (n ~ 1000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin (ASA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg od (n~1000)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (15 mg)</intervention_name>
    <description>Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:&#xD;
Left atrial enlargement ≥ 5.5 cm, OR&#xD;
Left atrial spontaneous echo contrast OR&#xD;
Left atrial thrombus OR&#xD;
Frequent ectopic atrial activity (&gt;1000/24 hours) on Holter ECG.</description>
    <arm_group_label>Rivaroxaban (15 mg)</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:&#xD;
Left atrial enlargement ≥ 5.5 cm, OR&#xD;
Left atrial spontaneous echo contrast OR&#xD;
Left atrial thrombus OR&#xD;
Frequent ectopic atrial activity (&gt;1000/24 hours) on Holter ECG.</description>
    <arm_group_label>Aspirin (ASA)</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. RVHD diagnosed by echocardiography at any time prior to enrollment&#xD;
&#xD;
          2. Age ≥18&#xD;
&#xD;
          3. Increased risk of stroke by any of the following&#xD;
&#xD;
               1. CHA2DS2-VASc score ≥ 2 OR&#xD;
&#xD;
               2. Moderate/Severe mitral stenosis with valve area ≤2.0 cm2 OR&#xD;
&#xD;
               3. Left atrial spontaneous echo contrast OR&#xD;
&#xD;
               4. Left atrial thrombus&#xD;
&#xD;
          4. Heart Rhythm&#xD;
&#xD;
               1. AF or Flutter and unsuitable for VKA therapy. (AF or Flutter should be documented&#xD;
                  on baseline 12-lead ECG, or on a previous 12-lead ECG, Holter monitor,&#xD;
                  in-hospital ECG rhythm strip or Pacemaker or ICD electrogram). OR&#xD;
&#xD;
               2. In the absence of AF or Flutter, patients would be eligible in the presence of&#xD;
                  any one of the following:&#xD;
&#xD;
               1. Left atrial enlargement ≥5.5 cm OR&#xD;
&#xD;
               2. Left atrial spontaneous echo contrast OR&#xD;
&#xD;
               3. Left atrial thrombus OR&#xD;
&#xD;
               4. Frequent ectopic atrial activity (&gt;1000/24 hours) on Holter monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to give informed consent&#xD;
&#xD;
          2. Actively involved in any study that would compromise the protocol of INVICTUS Trial&#xD;
&#xD;
          3. Severe co-morbid condition with life expectancy &lt; 1 year&#xD;
&#xD;
          4. Other serious condition(s) or logistic factors likely to interfere with study&#xD;
             participation or with the ability to complete the trial, as appropriate to country or&#xD;
             region.&#xD;
&#xD;
          5. Likely to have valve replacement surgery within 6 months&#xD;
&#xD;
          6. Mechanical valve prosthesis or other condition requiring treatment with VKAs. Patients&#xD;
             with deep vein thrombosis or recent pulmonary embolism can be enrolled where both VKAs&#xD;
             and rivaroxaban are approved.&#xD;
&#xD;
          7. Contraindication to the study medication of the trial&#xD;
&#xD;
               -  Allergy to rivaroxaban&#xD;
&#xD;
               -  Allergy to VKAs ( non-inferiority trial)&#xD;
&#xD;
               -  Allergy to aspirin ( superiority trial)&#xD;
&#xD;
          8. Severe renal insufficiency with an calculated creatinine clearance (Cockcroft-Gault)&#xD;
             &lt;15 ml/min&#xD;
&#xD;
          9. Serious bleeding in the past six months or at high risk for bleeding&#xD;
&#xD;
         10. Moderate to severe hepatic impairment&#xD;
&#xD;
         11. Ongoing need for dual antiplatelet therapy (patients with on-going aspirin therapy&#xD;
             ≤100 mg per day are not excluded)&#xD;
&#xD;
         12. Ongoing need for dual strong inhibitors of CYP-3a4 or p-glycoprotein inhibitor.&#xD;
&#xD;
         13. Received an investigational drug in the past 30 days&#xD;
&#xD;
         14. Patients considered unsuitable for trial inclusion because of unwillingness to attend&#xD;
             follow up visits&#xD;
&#xD;
         15. Women who are pregnant and/or breastfeeding&#xD;
&#xD;
         16. Women of child bearing age who do not use an effective form of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>cumulative participant data only</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

